背景:脑脉通注射液是治疗缺血性脑血管病的中药复方制剂,具有拮抗钙超载,调节前列素与血栓素系统的失衡状态,阻断自由基介导的脂质过氧化反应而保护大脑.目的:观察脑脉通注射液对大鼠脑组织含水量和Ca2+含量、超氧化物歧化酶活性、脂质过氧化物、6-酮-前列素1α、血栓素水平的影响,并与复方丹参注射液做比较.设计:随机对照实验.单位:成都中医药大学实验中心.材料:实验于1997-10/1998-02成都中医药大学实验中心完成.选择健康雄性Wistar大鼠72只,随机分为6组,每组12只.①正常对照组:不进行模型制备,自由饮水,常规饲养.②模型组:腹腔注射生理盐水1.67 mL/kg,2次/d.③复方丹参注射液1.67 mL/kg组:腹腔注射复方丹参注射液1.67 mL/kg,2次/d.④脑脉通注射液3.33,1.67,0.84 mL/kg组:腹腔注射脑脉通注射液3.33,1.67,0.84 mL/kg,2次/d.方法:各组大鼠用药48 h后,于麻醉状态下快速断头处死,立即取出脑组织,从两半球中间切开分成两份,一份在低温下制备脑组织匀浆采用放射免疫分析法待测6-酮-前列素1α和血栓素B2水平评估前列素与血栓素系统的平衡状态、采用改进的邻苯三酚自氧化法和硫代巴比妥酸比色法检测超氧化物岐化酶活性和脂质过氧化物水平评估自由基介导的脂质过氧化情况.另一份立即在电子天平上称取干、湿重,计算脑组织含水量评估脑水肿情况.采用原子吸收分光光度法检测脑组织Ca2+含量评估钙超载情况.主要观察指标:①各组大鼠脑组织含水量和Ca2+含量.②各组大鼠脑组织超氧化物歧化酶活性、脂质过氧化物含量.③各组大鼠脑组织6-酮-前列素1α和血栓素B2含量.结果:72只大鼠均进入结果分析.①各组大鼠脑组织含水量和Ca2+含量:模型组明显高于正常组[(82.27±1.32)%,(77.24±1.36)%;(267.47±15.69),(37.55±13.23)μg/g,P<0.01],4个治疗组的脑组织含水量均有不同程度的减轻,脑脉通注射液3.33 mL/kg组效应最强[78.74±1.41)%],复方丹参注射液1.67 mL/kg组最弱[(81.45±1.52)%].复方丹参注射液各组Ca2+含量均有不同程度降低,存在剂量效应依赖性,而复方丹参注射液1.67 mL/kg组Ca2+含量与模型组接近[(253.66±12.85)μg/g,P>0.05].②各组大鼠脑组织超氧化物歧化酶活性、脂质过氧化物含量:模型组超氧化物歧化酶活性明显低于正常组[(86.18±3.17),(131.86±4.67)μkat/g,P<0.01],经过治疗后脑脉通3个剂量组的超氧化物歧化酶活性均有提高,存在剂量效应依赖性(P<0.01),脑脉通注射液3.33 mL/kg组效应最强[(119.02±4.00)μkat/g],复方丹参注射液1.67 mL/kg组超氧化物歧化酶活性与模型组接近(P>0.05).模型组脂质过氧化物含量高于正常组[(52.46±3.25),(32.29±2.23)μmo1/L,P<0.01],各治疗组的脂质过氧化物含量均显著低于模型组,而脑脉通注射液3.33,1.67,0.84 mL/kg组的疗效优于复方丹参注射液1.67 mL/kg组[(35.68±2.86),(41.54±2.47),(45.71±3.14),(47.8 4±2.71)μmol/L,P<0.01].③各组大鼠脑组织6-酮-前列素1α和血栓素B2含量:模型组脑组织6-酮-前列素1α含量明显低于正常组(P<0.01),4个治疗组均能提高6-酮-前列素1α含量,脑脉通注射液3.33,1.67,0.84 mL/kg组的疗效优于复方丹参注射液1.67 mL/kg组[(43.84±2.98),(35.01±4.32),(29.97±3.81),(22.89±3.64)ng/g,P <0.01].模型组脑组织血栓素B2含量明显高于正常组(P<0.01),经治疗后4个治疗组与模型组比较均能显著降低脑组织血栓素B2含量,且存在剂量差异,而复方丹参注射液1.67 mL/kg组的效果低于脑脉通注射液3.33,1.67,0.84 mL/kg组[(40.58±1.34),(32.85±1.43),(34.31±1.39),(37.27±1.52)ng/g,P<0.01].结论:脑脉通注射液可减轻脑水肿、拮抗钙离子、调节血栓素和前列腺素系统失衡、提高抗氧化酶活性和抗自由基损伤作用,从而起到保护脑组织结构和功能的治疗效应,且有一定的效量关系,脑脉通注射液的效果优于复方丹参注射液.
揹景:腦脈通註射液是治療缺血性腦血管病的中藥複方製劑,具有拮抗鈣超載,調節前列素與血栓素繫統的失衡狀態,阻斷自由基介導的脂質過氧化反應而保護大腦.目的:觀察腦脈通註射液對大鼠腦組織含水量和Ca2+含量、超氧化物歧化酶活性、脂質過氧化物、6-酮-前列素1α、血栓素水平的影響,併與複方丹參註射液做比較.設計:隨機對照實驗.單位:成都中醫藥大學實驗中心.材料:實驗于1997-10/1998-02成都中醫藥大學實驗中心完成.選擇健康雄性Wistar大鼠72隻,隨機分為6組,每組12隻.①正常對照組:不進行模型製備,自由飲水,常規飼養.②模型組:腹腔註射生理鹽水1.67 mL/kg,2次/d.③複方丹參註射液1.67 mL/kg組:腹腔註射複方丹參註射液1.67 mL/kg,2次/d.④腦脈通註射液3.33,1.67,0.84 mL/kg組:腹腔註射腦脈通註射液3.33,1.67,0.84 mL/kg,2次/d.方法:各組大鼠用藥48 h後,于痳醉狀態下快速斷頭處死,立即取齣腦組織,從兩半毬中間切開分成兩份,一份在低溫下製備腦組織勻漿採用放射免疫分析法待測6-酮-前列素1α和血栓素B2水平評估前列素與血栓素繫統的平衡狀態、採用改進的鄰苯三酚自氧化法和硫代巴比妥痠比色法檢測超氧化物岐化酶活性和脂質過氧化物水平評估自由基介導的脂質過氧化情況.另一份立即在電子天平上稱取榦、濕重,計算腦組織含水量評估腦水腫情況.採用原子吸收分光光度法檢測腦組織Ca2+含量評估鈣超載情況.主要觀察指標:①各組大鼠腦組織含水量和Ca2+含量.②各組大鼠腦組織超氧化物歧化酶活性、脂質過氧化物含量.③各組大鼠腦組織6-酮-前列素1α和血栓素B2含量.結果:72隻大鼠均進入結果分析.①各組大鼠腦組織含水量和Ca2+含量:模型組明顯高于正常組[(82.27±1.32)%,(77.24±1.36)%;(267.47±15.69),(37.55±13.23)μg/g,P<0.01],4箇治療組的腦組織含水量均有不同程度的減輕,腦脈通註射液3.33 mL/kg組效應最彊[78.74±1.41)%],複方丹參註射液1.67 mL/kg組最弱[(81.45±1.52)%].複方丹參註射液各組Ca2+含量均有不同程度降低,存在劑量效應依賴性,而複方丹參註射液1.67 mL/kg組Ca2+含量與模型組接近[(253.66±12.85)μg/g,P>0.05].②各組大鼠腦組織超氧化物歧化酶活性、脂質過氧化物含量:模型組超氧化物歧化酶活性明顯低于正常組[(86.18±3.17),(131.86±4.67)μkat/g,P<0.01],經過治療後腦脈通3箇劑量組的超氧化物歧化酶活性均有提高,存在劑量效應依賴性(P<0.01),腦脈通註射液3.33 mL/kg組效應最彊[(119.02±4.00)μkat/g],複方丹參註射液1.67 mL/kg組超氧化物歧化酶活性與模型組接近(P>0.05).模型組脂質過氧化物含量高于正常組[(52.46±3.25),(32.29±2.23)μmo1/L,P<0.01],各治療組的脂質過氧化物含量均顯著低于模型組,而腦脈通註射液3.33,1.67,0.84 mL/kg組的療效優于複方丹參註射液1.67 mL/kg組[(35.68±2.86),(41.54±2.47),(45.71±3.14),(47.8 4±2.71)μmol/L,P<0.01].③各組大鼠腦組織6-酮-前列素1α和血栓素B2含量:模型組腦組織6-酮-前列素1α含量明顯低于正常組(P<0.01),4箇治療組均能提高6-酮-前列素1α含量,腦脈通註射液3.33,1.67,0.84 mL/kg組的療效優于複方丹參註射液1.67 mL/kg組[(43.84±2.98),(35.01±4.32),(29.97±3.81),(22.89±3.64)ng/g,P <0.01].模型組腦組織血栓素B2含量明顯高于正常組(P<0.01),經治療後4箇治療組與模型組比較均能顯著降低腦組織血栓素B2含量,且存在劑量差異,而複方丹參註射液1.67 mL/kg組的效果低于腦脈通註射液3.33,1.67,0.84 mL/kg組[(40.58±1.34),(32.85±1.43),(34.31±1.39),(37.27±1.52)ng/g,P<0.01].結論:腦脈通註射液可減輕腦水腫、拮抗鈣離子、調節血栓素和前列腺素繫統失衡、提高抗氧化酶活性和抗自由基損傷作用,從而起到保護腦組織結構和功能的治療效應,且有一定的效量關繫,腦脈通註射液的效果優于複方丹參註射液.
배경:뇌맥통주사액시치료결혈성뇌혈관병적중약복방제제,구유길항개초재,조절전렬소여혈전소계통적실형상태,조단자유기개도적지질과양화반응이보호대뇌.목적:관찰뇌맥통주사액대대서뇌조직함수량화Ca2+함량、초양화물기화매활성、지질과양화물、6-동-전렬소1α、혈전소수평적영향,병여복방단삼주사액주비교.설계:수궤대조실험.단위:성도중의약대학실험중심.재료:실험우1997-10/1998-02성도중의약대학실험중심완성.선택건강웅성Wistar대서72지,수궤분위6조,매조12지.①정상대조조:불진행모형제비,자유음수,상규사양.②모형조:복강주사생리염수1.67 mL/kg,2차/d.③복방단삼주사액1.67 mL/kg조:복강주사복방단삼주사액1.67 mL/kg,2차/d.④뇌맥통주사액3.33,1.67,0.84 mL/kg조:복강주사뇌맥통주사액3.33,1.67,0.84 mL/kg,2차/d.방법:각조대서용약48 h후,우마취상태하쾌속단두처사,립즉취출뇌조직,종량반구중간절개분성량빈,일빈재저온하제비뇌조직균장채용방사면역분석법대측6-동-전렬소1α화혈전소B2수평평고전렬소여혈전소계통적평형상태、채용개진적린분삼분자양화법화류대파비타산비색법검측초양화물기화매활성화지질과양화물수평평고자유기개도적지질과양화정황.령일빈립즉재전자천평상칭취간、습중,계산뇌조직함수량평고뇌수종정황.채용원자흡수분광광도법검측뇌조직Ca2+함량평고개초재정황.주요관찰지표:①각조대서뇌조직함수량화Ca2+함량.②각조대서뇌조직초양화물기화매활성、지질과양화물함량.③각조대서뇌조직6-동-전렬소1α화혈전소B2함량.결과:72지대서균진입결과분석.①각조대서뇌조직함수량화Ca2+함량:모형조명현고우정상조[(82.27±1.32)%,(77.24±1.36)%;(267.47±15.69),(37.55±13.23)μg/g,P<0.01],4개치료조적뇌조직함수량균유불동정도적감경,뇌맥통주사액3.33 mL/kg조효응최강[78.74±1.41)%],복방단삼주사액1.67 mL/kg조최약[(81.45±1.52)%].복방단삼주사액각조Ca2+함량균유불동정도강저,존재제량효응의뢰성,이복방단삼주사액1.67 mL/kg조Ca2+함량여모형조접근[(253.66±12.85)μg/g,P>0.05].②각조대서뇌조직초양화물기화매활성、지질과양화물함량:모형조초양화물기화매활성명현저우정상조[(86.18±3.17),(131.86±4.67)μkat/g,P<0.01],경과치료후뇌맥통3개제량조적초양화물기화매활성균유제고,존재제량효응의뢰성(P<0.01),뇌맥통주사액3.33 mL/kg조효응최강[(119.02±4.00)μkat/g],복방단삼주사액1.67 mL/kg조초양화물기화매활성여모형조접근(P>0.05).모형조지질과양화물함량고우정상조[(52.46±3.25),(32.29±2.23)μmo1/L,P<0.01],각치료조적지질과양화물함량균현저저우모형조,이뇌맥통주사액3.33,1.67,0.84 mL/kg조적료효우우복방단삼주사액1.67 mL/kg조[(35.68±2.86),(41.54±2.47),(45.71±3.14),(47.8 4±2.71)μmol/L,P<0.01].③각조대서뇌조직6-동-전렬소1α화혈전소B2함량:모형조뇌조직6-동-전렬소1α함량명현저우정상조(P<0.01),4개치료조균능제고6-동-전렬소1α함량,뇌맥통주사액3.33,1.67,0.84 mL/kg조적료효우우복방단삼주사액1.67 mL/kg조[(43.84±2.98),(35.01±4.32),(29.97±3.81),(22.89±3.64)ng/g,P <0.01].모형조뇌조직혈전소B2함량명현고우정상조(P<0.01),경치료후4개치료조여모형조비교균능현저강저뇌조직혈전소B2함량,차존재제량차이,이복방단삼주사액1.67 mL/kg조적효과저우뇌맥통주사액3.33,1.67,0.84 mL/kg조[(40.58±1.34),(32.85±1.43),(34.31±1.39),(37.27±1.52)ng/g,P<0.01].결론:뇌맥통주사액가감경뇌수종、길항개리자、조절혈전소화전렬선소계통실형、제고항양화매활성화항자유기손상작용,종이기도보호뇌조직결구화공능적치료효응,차유일정적효량관계,뇌맥통주사액적효과우우복방단삼주사액.
BACKGROUND: Naomaitong injection is a Chinese herbal compound preparation for treatment of ischemic cerebral vascular disease, acting on resisting calcium overload, regulating the imbalance between thromboxane (TXA) and prostaglandin (PG) and blocking lipid peroxidation mediated by free radical so as to protect cerebrum.OBJECTIVE: To observe the effects of naomaitong injection on water and Ca2+ contents, activity of superoxide dismutase (SOD), levels of lipid peroxide (LPO), 6-keto-PG lα and TXA, and compare it with danshen injection.DESIGN: Randomized control experiment was designed.SETTING: Experimental Center of Chengdu University of Traditional Chinese Medicine.MATERIALS: The experiment was performed in Experimental Center of Chengdu University of Traditional Chinese Medicine from October 1997 to February 1998, in which, 72 healthy male Wistar rats were employed, rangroup: Abdominal injection was done with physiological saline 1.67 mL/kg,group): Abdominal injection was done with compound danshen injection groups (naomaitong No.1, No.2 and No.3 groups): abdominal injection was done with naomaitong injection 3.33, 1.67, 0.84 mL/kg successively,twice/day.METHODS: Totally 48 hours after medication, under anesthetized state,the rats in every group were sacrificed to collect brain tissue. The two hemispheres were cut into two pieces from the middle. One of them was prepared into brain tissue homogenate at low temperature. Radioimmunologic analysis method was used to measure 6-keto-PG 1o and TXA B2 levels so as to evaluate the balance between PG and TXA systems. The modified pyorgallol autoxidation and thiobarbituric acid (TBA) colorimetric method were applied to determine SOD activity and LPO level respectively so as to evaluate lipid peroxidation mediated by free radical. The dry and wet weights of other piece were weighed immediately on electronic scale and the water content of brain tissue was calculated to evaluate brain edema. Atomic absorption spectrophotometry (AAS) was used to determine Ca2+content in brain tissue so as to evaluate calcium overload.tissue of rats in every group.content in brain tissue of rats in every group: That in model group was higher remarkably than normal group [(82.27±1.32)%, (77.24±1.36)%;(267.47±15.69), (37.55±13.23) μg/g, P < 0.01]. The water contents in 4 treatment groups were decreased of various degrees. The effect in No.1 group was the strongest [(78.74±1.41)%] and that in danshen group was the weakest [(81.45±1.52)%]. Ca2+ content in danshen group was decreased of various degrees, indicating dose-effect dependence, but, which was near to ty and LPO level in brain tissue of rats in every group: SOD activity in model group was lower remarkably than normal group [(86.18 ±3.17),(131.86±4.67) μkat/g, P < 0.01]. After treated with naomaitong of 3 dosages, that was all improved, indicating dose-effect dependence (P < 0.01). The effect of No.1 group was the strongest [(119.02±4.00) μkat/g],SOD activity in danshen group was near to model group (P > 0.05). LPO level in model group was higher than normal group [(52.46 ±3.25),(32.29±2.23) μmol/L, P < 0.01]. LPO level of every treatment group was lower significantly than model group and the therapeutic effects of No. 1, 2,3 groups were superior to danshen group [(35.68±2.86), (41.54±2.47),1α and TXA B2 in brain tissue of rats in every group: Content of 6-ketoPG 1α in brain tissue of model group was lower remarkably than normal group (P < 0.01). That was improved in all of 4 treatment groups, in which,the therapeutic effects of No.1, 2, 3 groups were superior to danshen group [(43.84±2.98), (35.01±4.32), (29.97±3.81), (22.89±3.64) ng/g, P < 0.01].TXA B2 content in brain tissue of model group was higher remarkably than normal group (P < 0.01). After treatment, the 4 treatment groups lowed significantly TXA B2 content in brain tissue compared with model group,indicating dose difference. That in danshen group was lower than No. 1, 2,3 groups [(40.58±1.34), (32.85±1.43), (34.31±1.39), (37.27±1.52) ng/g, P <0.01].CONCLUSION: Naomaitong injection alleviates brain edema, resists calcium ion, regulates imbalance between TXA and PG systems, improves activity of anti-oxidase and is against injury of free radical so as to protect the structure of brain tissue and achieve therapeutic effects, indicating a certain dose-effect relationship. The effect of naomaitong injection is superior to that of compound danshen injection.